Sage Japan 日本と言う

The Sage Group, Inc. has partnered with Gemseki in Tokyo to extend our global reach into Japan and Korea. The principal objective is to broaden Sage's strategic licensing, M&A and partnering capabilities for our healthcare clients in pharmaceuticals, biopharmaceuticals, biotechnology, diagnostics and medical technology. This will build upon Sage’s 25 years of  experience in such transactions.

The Sage Group now offers clients a full strategic advisory service including:

  • Assisting our clients in the West with licensing their pharma, diagnostic and medtech assets into the dynamic healthcare market in the Japan

  • Assisting Japanes companies with out-licensing their assets into global markets with a focus on North America and Europe

 

Gemseki Inc. (https://www.gemseki.com/en) is a leading open innovation platform company based in Japan, which actively facilitates and supports licensing and partnering transactions. The company was spun out from SNBL in 2017 (https://www.snbljapan.com/). SNBL is a listed company on the Tokyo Stock Exchange and the largest preclinical CRO in Japan.

 

Gemseki has initiated a very innovative approach towards the business development process in the life science industry by operating a ‘Drug Candidate Marketplace’, a platform for licensing and partnering, and is supporting more than 200 active assets for licensing as of June 2020. 

Hideyuki Hirama, President and CEO of Gemseki, has a Bachelor’s Degree in Law from the University of Tokyo and an MBA from Harvard University. He was for six years a Board Member in charge of strategy and corporate development for SNBL, a listed company on the Tokyo Stock Exchange and the largest preclinical Contract Research Organization (CRO) in Japan. Hideyuki has completed numerous licensing and partnering programs as well as mergers & acquisitions and investments. Before moving into life science fields, he worked at one of the biggest financial groups in Japan and engaged in corporate finance and investment banking activities. He is based in Tokyo, Japan.

 

The June 2020 issue of Industry Era, a U.S. technology magazine, featured Gemseki President and CEO, Hideyuki Hirama, as one of the “10 most inspiring CEOs to watch in 2020.” The article discusses how Gemseki is facilitating open innovation though its online ‘Drug Candidate Marketplace’, where drug candidates are listed and available for partnering. Mr. Hirama stated, “We strive to make contributions to humanity and society by supporting the best development of valuable drug candidates”.

For a confidential discussion in more detail, please email us at Japan@sagehealthcare.com.

For more information about The Sage Group and opportunities for collaboration with Sage Japan services, please visit our website, www.sagehealthcare.com, or contact:

US Corporate Office

The Sage Group Inc.

1802 Route 31 North, #381

Clinton, NJ 08809  USA

Attn: Wayne Pambianchi

Phone: +1 908-2319644

wpambianchi@sagehealthcare.com

EU Corporate Office

Sage Healthcare Ltd.

The Old Black Barns

Lord’s Lane, Ousden, Newmarket  CB8 8TX  UK

Attn: Dr. Bill Mason

Phone: +44 1638 500775

Mob: +44 7785 950134

wtm@sagehealthcare.com

Sage Japan Corporate Office (Gemseki)

Hideyuki Hirama
President and CEO
Gemseki Inc.

St Luke's Tower 28th Floor

8-1 Akashi-cho, Chuo-ku

Tokyo,104-0044

Japan
Email: hh@sagehealthcare.com
Tel: +81 3 6264 0471